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Summary  
Repair of tissue damaged during inflammatory processes is key to the return of local 
homeostasis and restoration of epithelial integrity. Here we define CD161+ regulatory T cells 
(Tregs) as a distinct, highly suppressive, population of Tregs mediating wound-healing. These 
Tregs were enriched in intestinal lamina propria, particularly in Crohn’s disease. CD161+ 
Tregs had a retinoic acid (ATRA) gene signature and CD161 expression on Tregs could be 
induced by ATRA, which directly regulated the CD161 gene. CD161 itself was co-
stimulatory and its ligation with the T-cell receptor induced cytokines that accelerated wound-
healing of intestinal epithelial cells. We identified a transcription factor network, including 
BACH2, RORgt, FOSL2, AP-1 and RUNX1, controlling expression of the wound-healing 
program and found that a CD161+ Treg signature in Crohn’s disease mucosa associated with 
reduced inflammation. These findings identify CD161+ Tregs as a population critical for 
controlling the balance between inflammation and epithelial barrier healing in the gut. 
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Introduction 
Regulatory T cell (Tregs) are a non-redundant, suppressive, subset of CD4+ helper T 
(Th) cells that are critical for the prevention of autoimmunity1. They are ideal candidates for 
cell-based clinical immunotherapy of autoimmunity and for prevention of transplant 
rejection2. Tregs express the master transcription factor (TF) FOXP3, the IL-2 receptor 
component CD25, the inhibitory co-receptor CTLA43,4 and depend on  the TF BACH25 for 
differentiation in the thymus (“tTregs”) and the periphery (“pTregs”). 
Conventional T cells (Tconv) are characterized by their own master TFs; these 
include T-BET for anti-viral Th1 cells, GATA3 for anti-helminth Th2 cells and RORγt for 
anti-bacterial and anti-fungal Th17 cells, respectively6. These TFs were initially considered to 
antagonize Treg development: in mice, induction of high T-bet expression in Tregs within 
inflamed bowel drives Tregs into a pro-inflammatory phenotype reminiscent of Th1 cells7. 
This view has been challenged by the investigation of mice with deletion of these factors 
specifically within FoxP3+ cells8-11. For example, T-bet expression within FoxP3+ Tregs is 
required for trafficking to and suppression of Th1-mediated inflammation10, and Gata3 is 
required for full Treg function in the gut11. These findings support a “compartmentalized” 
view of Tregs, suggesting that there are multiple sub-populations of Tregs defined by the 
expression of transcription factors associated with effector cell lineages and by their ability to 
suppress particular immune cell responses or to carry out other specialized functions. Indeed, 
it is now recognized that the TF circuitry of Tregs is complex, with significant interplay 
between FoxP3 and other lineage-associated TFs12,13. 
In humans, heterogeneous populations of Tregs have been reported, although these 
have been typically defined by surface markers rather than TFs. These include CD39, HLA-
DR and CD45RA, among others2. Whether these sub-populations translate into the ability to 
suppress specific parts of the human immune system has yet to be fully elucidated. We have 
previously shown that conventional methods of delineating Treg subsets are limited by the 
number of markers that can be concurrently used and by a biased approach to data analysis 
(gating of Treg subsets)14. This has led to conflicting results, with memory Tregs reported as 
both non-suppressive15 and highly suppressive16 by different groups. By contrast, an unbiased 
multi-dimensional analysis approach can delineate the most suppressive Treg sub-
populations, identify new ones and exclude those that are less likely to be regulatory14.  
Inflammatory bowel disease (IBD) represents a complex collection of disorders in 
which aberrant activation of the mucosal immune system, epithelial barrier dysfunction and 
microbial dysbiosis all contribute to chronic inflammation and unregulated local Th1 and 
Th17 responses17. Bowel mucosa is a key site for induction of pTregs from naïve CD4+ 
precursors via instruction from environmental factors, such as transforming growth factor 
(TGF)-b, IL-2 and all-trans retinoic acid (ATRA)18. Tregs mediate dominant tolerance in gut 
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mucosa, preventing or ameliorating colitis on adoptive transfer in murine models19. 
Conversely, FOXP3 mutations or disruption of other molecules key to Tregs (e.g. CTLA-4, 
IL-10R, TGF-b) cause enteropathy in both humans and mice4,20,21, again demonstrating a key 
role for these cells in preventing gut inflammation. Lamina propria Tregs are expanded in 
patients with IBD, but it is unclear why they are unable to control local inflammation or what 
function(s) they perform in these diseases22,23. We and others have shown that Tregs can 
express RORgt together with IL-17A, and that in humans these predicates are restricted to a 
subset of Tregs expressing CD16124-26. CD161 is a C-type lectin-like receptor, encoded on 
human chromosome 12 and expressed on the cell surface of human NK cells27 and various 
subsets of T lymphocytes28. CD161+ conventional Th cells are memory T cells that act as 
Th17 precursors29,30. The cognate ligand for CD161 is lectin like transcript 1 (LLT1)31, in 
which single nucleotide polymorphisms (SNPs) associate with human IBD on genome-wide 
association studies32, suggesting that the CD161-LLT1 interaction is physiologically 
important.  
Here, we delineate the biological repertoire of CD161+ Tregs, their role in the 
immune system and their mechanisms of action. Our data show that CD161+ Tregs are a 
highly suppressive and distinct subset of induced Tregs that are enriched in active areas of 
IBD, and that expression of CD161 is induced by ATRA. Functionally, they are highly 
suppressive and produce soluble factors, a property co-stimulated by ligation of CD161 itself. 
Their regulome, assessed by ATAC-seq, points to a TF circuitry that includes the TFs 
BACH2, RORgt and AP-1 family members, genes that mediate wound healing. Cytokines 
from these cells accelerate wound healing of colorectal epithelium, suggesting that CD161+ 
Tregs may play a critical role in the patho-physiology of IBD and could theoretically be used 
as cellular products for the treatment of these diseases. Accordingly, we report that a CD161+ 
Treg signature in the mucosa of Crohn’s disease is associated with ameliorated inflammation.   
Results 
CD161-expressing Tregs are a discrete Treg population with a distinct TCRVb repertoire  
We used an unbiased multi-dimensional analysis pipeline via cytometry by time-of-
flight (CyTOF) to identify and study biologically important human Treg sub-populations. 
Visualized stochastic neighbor embedding (viSNE) was used to create a map of CD4+ T cells 
freshly isolated from blood and arrange cells along t-distributed stochastic neighbor 
embedding (t-SNE) axes based on per-cell phenotypic similarity14,33,34 (Fig. 1a-b). Tregs, 
identified by high expression of CD25 and FOXP3 and low expression of CD127, clustered 
together and could be resolved into naïve and memory Treg populations (Fig. 1a-b). 
Likewise, Tconv, identifiable by low CD25 and FOXP3 and high CD127 expression, 
clustered together and distinctly from Tregs (Fig. 1a-b). In this unsupervised analysis, the C-
type lectin CD161 was expressed by a sub-population of memory Tregs 
(CD4+CD25+CD127loFOXP3+CD45RA–CD45RO+) and a group of memory Tconv (broadly 
CD4+CD25–CD127+FOXP3–CD45RAloCD45RO+) (Fig. 1a-b). To identify distinct clusters of 
T cells, we performed a spanning-tree progression analysis of density-normalized events 
(SPADE)35 based on t-SNE values. Differential expression of different markers within each 
identified SPADE node was used to further cluster T cells. This analysis resolved CD4+ T 
cells into 50 sub-populations, grouped into four main populations: naïve Tregs, memory 
Tregs, naïve Tconv and memory Tconv, each characterized by a different expression profile 
(Fig. 1c and Supplementary Fig. 1a). CD161-expressing cells represented a distinct sub-
population of memory Tregs and several sub-populations of memory Tconv, which were all 
distinct from Tregs (Fig. 1c). In order to further distinguish Tregs from Tconv, we performed 
a similar analysis of transcriptomes by single-cell RNA-seq using CD4+CD25+ cells as input 
(Supplementary Figs. 1b-e). This pipeline resolved cells into 9 clusters, of which two were 
Tregs (clusters 0 and 3), five were Tconv (clusters 1, 2, 4, 5 and 6) and two were probably 
Tregs, although too small in number to sub-categorize (clusters 7 and 8) (Supplementary 
Figs. 1b-e). The two Treg clusters (clusters 0 and 3) were clearly separate from the Tconv 
clusters and one of them (cluster 3) expressed KLRB1, the gene encoding CD161 
(Supplementary Figs. 1b-e). Consistent with our CyTOF data, expression of KLRB1 in the 
CD161+ Treg population was lower than that in the CD161+ Tconv sub-population. A 
heatmap of Treg markers (IL2RA, IL7R, FOXP3), KLRB1 and naïve/memory markers 
(CD62L and CCR7) confirmed clustering of the CD161+ Tregs (cluster 3) independently from 
Tconv cells (Supplementary Fig. S1e) and was similar to heatmaps constructed from protein 
expression derived by CyTOF (Supplementary Fig. 1f). A similar unsupervised pipeline 
applied to CD4+ T cells flow-stained with just 5 markers, CD4, CD25, CD127, CD45RA and 
CD161 produced similar viSNE and SPADE plots to mass cytometry (Supplementary Fig. 
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1g-h) and could be used to FACS-sort Treg sub-populations from peripheral blood for further 
analysis (Supplementary Figs. 1i-j). Henceforth, these Tregs are referred to as “CD161+ 
Tregs” (CD4+CD25hiCD127loCD45RA–CD161+; denoted in purple), “naïve Tregs” 
(CD4+CD25hiCD127loCD45RA+CD161–; denoted in orange) and CD161– memory Tregs, 
abbreviated to “memory Tregs” (CD4+CD25hiCD127loCD45RA–CD161–; denoted in yellow). 
T cell CD161 expression is associated with a restricted range of T cell receptors 
(TCRs): TCR Va7.2 in mucosal-associated invariant T (MAIT) cells28 and invariant TCR 
Va24-Ja18 in iNKT cells36. Neither TCR was significantly enriched in CD161+ Tregs 
(Supplementary Fig. 1k). To determine the clonality of CD161+ Tregs and their relationship 
to other Tregs and Tconv, we TCRVB sequenced the three populations of Tregs as well as 
Tconv (defined as CD4+CD25–CD127+) and CD161+ Tconv (defined as CD4+CD25–
CD127+CD45RO+CD161+) as controls. Among the TCRBV families, the three highest 
contributors to the total TCR repertoire (BV05, BV06 and BV07) and one of the lower 
contributors (BV19) were chosen to represent the variability of the cellular repertoire by 
spectratyping. CD161+ Tregs were polyclonal, had normally distributed CDR3 length in the 
different TCRBV families (Fig. 1d) and a similar contribution to the overall TCR repertoire 
compared with other T cell subsets (Supplementary Fig. 1l). We then asked whether the total 
TCR repertoire of CD161+ Tregs overlapped with either the Treg or Tconv populations. We 
found limited clonality shared between the different subsets; in particular, CD161+ Tregs 
shared only 4.5% and 4.8% of their TCR sequences with Memory Tregs and CD161+ Tconv 
cells, respectively (Supplementary Fig. 1m). We next calculated the Morisita-Horn 
similarity index to measure the TCR composition overlap between the different T cell 
populations37. This index ranges between 0 (minimal similarity) and 1 (maximal similarity). 
Analysis showed limited TCR repertoire overlap between any of the populations other than 
between CD161+ Tconv and Tconv (a value of 0.413) (Fig. 1e). Hierarchical clustering of the 
samples, based on the Morisita-Horn similarity index, showed two subdivisions, separating 
the two Tconv populations from all three Treg populations; moreover, CD161+ Tregs 
clustered with memory Tregs within the regulatory T cell main branch (Fig. 1f). These data 
indicate that CD161+ Tregs have a distinct TCR repertoire from other Tregs and do not 
represent a clonal expansion from a Tconv population. 
CD161+ Tregs share features with both CD161+ Tconv and classical Tregs  
To identify similarities and differences between the 3 sub-populations, we first 
compared their transcriptomes using microarray and Gene Set Enrichment Analysis (GSEA) 
(Supplementary Fig. 2a-d). Despite CD161+ Tregs being a sub-population of memory Tregs, 
there were 549 genes differentially expressed when comparing CD161+ to memory Tregs 
(Fig. 2a, Supplementary Fig. 2b-d and Supplementary Table 1). CD161+ Tregs were 
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enriched in genes expressed by other CD161+ cells28 and also expressed the core 
transcriptional profile of Tregs38 (Fig. 2b-c and Supplementary Fig. 2e-f). This data 
suggested that, in addition to core Treg genes they express a range of other transcripts related 
to CD161 induction or signalling. 
All three Treg populations had similar FOXP3 protein expression (Fig. 2d). 
Epigenetic modifications, notably the degree of methylation of the Treg-specific 
demethylation region (TSDR) within the FOXP3 gene locus, can give an indication of the 
stability of FOXP3 expression, with tTregs having a demethylated locus and more stable 
FOXP3 expression, compared with iTregs that retain higher region methylation39. We next 
measured the methylation status of the FOXP3 TSDR and two other key Treg-associated 
genes, IL2RA and CTLA4, in the three Treg populations and, for comparison, Tconv 
(Supplementary Fig. 2g). Methylation at IL2RA and CTLA4 loci were similar between the 
three Treg populations but distinct from the more highly methylated Tconv (Fig. 2e and 
Supplementary Fig. 2h). At the FOXP3 TSDR we noted CD161+ Tregs to have region 
methylation intermediate (55%) between naïve (25%) or memory (28%) Tregs and Tconv 
(88%) (Fig. 2e and Supplementary Fig. 2h). In summary, CD161+ Tregs express the Treg 
master TF FOXP3, same surface markers as Tregs, and express the Treg gene transcription 
profile. Their methylation pattern at key gene loci are similar to other Tregs, albeit with 
intermediate TSDR methylation.  
All-trans retinoic acid (ATRA) directly regulates CD161 expression 
We noted almost complete absence of CD161+ Tregs in human cord blood24 and 
thymus (our unpublished observations), suggesting that CD161+ Tregs are induced to develop 
or to specialize in the periphery. We have previously observed that long-term culture of Tregs 
with ATRA supports the persistence of cells expressing CD16140. We found significant 
enrichment of ATRA-regulated genes in CD161+ Tregs compared to memory Tregs (Fig. 3a) 
by GSEA, including two gut homing markers, CCR9 and ITGA4, which are classically 
regulated by ATRA (Fig. 3a and Supplementary Fig. 3a); CCR9 was confirmed at the 
protein level by flow cytometry (Supplementary Fig. 3b). Activation of freshly isolated 
Tregs with ATRA induced expression of both CCR9 and CD161 (Fig. 3b). Since Tregs 
interact with DCs in the gut, we determined if mature DCs generate ATRA via a functional 
assay for the key enzyme aldehyde dehydrogenase (ALDH). LPS-matured DCs expressed 
substantial amounts of this enzyme (Fig. 3c) together with lectin like transcript 1 (LLT1), the 
natural ligand for CD161 (data not shown)31. In the absence of DCs, Tregs lost expression of 
CD161; whereas co-culture of freshly isolated Tregs with DCs induced CD161. The addition 
of BMS493, a pan-retinoic acid receptor (RAR) inverse agonist blocked CD161 expression in 
a dose-dependent manner (Fig. 3d and Supplementary Fig. 3c). To see whether ATRA can 
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directly induce CD161, we scanned the KLRB1, which encodes CD161, and CCR9 gene loci 
(as control), for retinoic acid receptor alpha (RARA) DNA binding motifs (Supplementary 
Fig. 3d). One potential RARA binding site in KLRB1 and multiple sites in CCR9 were 
identified (Supplementary Fig. 3e). By ChIP-qPCR for RARA we found that ATRA 
enhanced RARA binding at both loci in T cells, evident as significant increment in percentage 
of input for both KLRB1 and CCR9 target sequences after culture with ATRA, compared to 
untreated cells (Fig. 3e). Collectively, these data indicate that ATRA can induce CD161 
expression on Tregs. 
CD161+ Tregs are a highly suppressive Treg population 
To study the function of CD161+ Tregs, we tested first their ability to suppress Tconv 
proliferation ex vivo by measuring the ratio of Tregs to Tconv required to suppress 
proliferation by 50% (IC50) for each population41 (Fig. 4a-b and Supplementary Fig. 4a-b). 
We found that CD161+ Tregs had a lower mean IC50 compared to memory Tregs while naïve 
Tregs did not reach 50% suppression ex vivo (and therefore IC50 could not be calculated) (Fig. 
4b and Supplementary Fig. 4b). CD161+ Tregs remained stably regulatory even after in 
vitro expansion (Supplementary Fig. 4c). Separation of Tregs from target cells by a 
transwell abrogated the majority of the suppressive function of CD161+ Tregs 
(Supplementary Fig. 4d), consistent with other Treg populations42. The presence of anti-
CD161, anti-PDL1, anti-TGFβRII or anti-IL-10R antibodies caused no significant impairment 
of CD161+ Treg suppression, indicating that suppressive function is likely not due to a single 
factor (Supplementary Fig. 4e). Furthermore, suppression assays carried out under Th1 and 
Th17 skewing conditions did not impair the regulatory function of CD161+ Tregs 
(Supplementary Fig. 2f).  CD161 is found on NK cells27 and cytotoxicity is a suppressive 
mechanism of some Tregs43. However, we found neither perforin nor granzyme (A or B) in 
any of the Treg populations (Supplementary Fig. 4g) and no evidence of Tconv cytolysis 
after co-culture with CD161+ Tregs (data not shown). 
The mouse CD161 ortholog is not expressed on T cells (Supplementary Table 2). 
To confirm suppressive ability of CD161+ Tregs in vivo, we used a humanised mouse model 
of severe xeno-graft versus host disease (GvHD) in NOD/scid/Il2rg−/− mice by injecting 
CD25-depleted human PBMC with or without in vitro expanded memory or CD161+ Tregs. 
Mice receiving either memory or CD161+ Tregs were protected from xeno-GvHD, surviving 
significantly longer than mice injected with PBMC alone. This was associated with a 
significant reduction in clinical disease scores (Fig. 4c). Thus, CD161+ Tregs had a 
comparable suppressive activity to traditional Tregs in vivo. These data indicate that CD161+ 
Tregs are highly regulatory both in vitro and in vivo. 
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CD161 ligation stimulates cytokine production in CD161+ Tregs 
 To determine the role of CD161 expression by Tregs, we first investigated the 
specific effects of TCR triggering by examining transcriptomes of Tregs stimulated with a-
CD3 + a-CD28 for 4hours. Approximately 1500 transcripts showed changes from baseline in 
CD161+ Tregs (Fig. 5a and Supplementary Fig. 5a-b). While a core set of transcripts, 
including KLRB1, RORC and CCR9 differed between CD161+ and memory Tregs both before 
and after these cells were activated, there was surprisingly little overlap (Fig. 5b-c). Of note, 
a number of cytokine genes, including IL10, IL17A, IL17F and IL21 (Fig. 5c), were enriched 
in CD161+ Tregs (Supplementary Fig. 5b). We confirmed preferential accumulation of IL-
10, IL-17A, IL-22 and IL-4, but not IFN-g, in three-day supernatants of aCD3/CD28-
activated CD161+ Tregs (Fig. 5d).  
 CD161 in Tconv is a marker of Th17 cells. Furthermore, CD161+ Tregs expressed 
RORC, the key TF of Th17 cells, along with IL-17 itself. We next determined whether IL-17 
production was compatible with suppressive function in CD161+ Tregs, by isolating IL-
17+CD161+ and IL-17–CD161+ Tregs using an IL-17 capture assay (Supplementary Fig. 5c-
d) and testing their respective suppressive functions. IL-17+CD161+ Tregs remained highly 
suppressive despite producing IL-17 (Fig. 5e).  
CD161 does not have a classical ITAM/ITIM domain but its ligation can have both 
activating and inhibitory functions, depending on cell type28,44,45. To assess the function of 
CD161 in Tregs, we stimulated cells with aCD3, aCD28 magnetic beads additionally coated 
with aCD161 or an IgG2 isotype. After three days of culture CD161 cross-linking 
significantly enhanced cytokine production from CD161+ Tregs (Fig. 5f), indicating that 
CD161 acts as a co-stimulatory molecule in CD161+ Tregs. Thus, CD161+ Tregs are a 
cytokine producing population of Tregs, CD161 co-ligation is co-stimulatory to this process 
and IL-17 production is compatible with preserved suppressive function.  
Genome-wide chromatin landscapes define regulatory circuitry in CD161+ Tregs 
 We next assessed the regulatory elements (REs) of naïve, memory and CD161+ Tregs 
directly ex vivo, hypothesizing that these dictate differences in biological function. We 
examined global chromatin landscapes using assay for transposase-accessible chromatin with 
high-throughput sequencing (ATAC-seq)46. Open chromatin regions (OCRs) surrounding the 
signature Treg-associated genes, notably FOXP3, CTLA4 and IL2RA were not significantly 
different between the three populations (Supplementary Fig. 6a). We focused on ~1300 
OCRs that have consistent patterns among all three biological replicates but differ among the 
three Treg populations. These regions were in three clusters: those specific to naïve Tregs 
(25% of total), specific to CD161+ Tregs (39% of the total) and those shared between CD161+ 
and memory Tregs (37% of the total) (Fig. 6a-b and Supplementary Table 3). Notable 
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examples of genes with OCRs specific to CD161+ Tregs include key cytokines, such as 
IL17A, transcription factors, such as PRDM1 and C-MAF, and chemokine receptors, 
including CCR9 (Supplementary Table 3). The genomic distributions of OCRs were similar 
in the three clusters, with the majority in intronic and intergenic regions (Supplementary 
Fig. 6b). 
 To determine potential TFs targeting distinct Treg regulomes, we searched for 
enrichment of known TF motifs above background within OCR clusters using HOMER (Fig. 
6c and Supplementary Fig. 6c). CD161+-specific OCRs were enriched for motifs of RORgt, 
RUNX, AP-1 family (e.g. BATF, FOSL2), and Cap’n’collar (CNC) family members that 
include BACH2 (Fig. 6c and Supplementary Fig. 6c). To test if these TFs could explain the 
transcriptional differences between CD161+ and memory Tregs, we performed GSEA for 
genes regulated by BACH2, RORgt, BATF, FOSL2 and RUNX1. CD161+ Tregs were 
significantly enriched for BACH2, RORgt, FOSL2 and RUNX1 regulated genes, compared to 
memory Tregs (Fig. 6d). Approximately 40% of the 549 genes differentially expressed 
between CD161+ and memory Tregs could be attributed to regulation by Bach2, Runx1, Rorc, 
Fosl2 and Batf in mice using knockout models5,47,48, with BACH2 responsible for the majority 
of the transcriptional differences (Fig. 6e). Expression of BACH2 itself was significantly 
reduced and RORC significantly elevated in freshly isolated CD161+ Tregs compared to the 
other Treg populations (Supplementary Fig. 6d), suggesting that alteration in the expression 
of these TFs could explain some of the transcriptional differences we have seen in/of their 
targets. Peripheral blood T cells from a patient heterozygous for a BACH2L24P mutation 
rendering her haploinsufficient for this transcription factor49 showed over-representation of 
the CD161+ Treg subset relative to controls (Fig. 6f), confirming that low BACH2 expression 
is important for development and/or persistence of these cells. An integrated network was 
constructed based on these effects to illustrate the transcriptional circuitry (Supplementary 
Fig. 6e). Genes controlled solely by BACH2 regulated cell division, whereas genes co-
regulated by BACH2 and the other TFs in this model were especially involved in wound 
healing (Fig. 6f). These data point to distinct regulomes in CD161+ Tregs imparting novel 
functions including wound-healing. 
 
CD161+ Tregs are enriched in IBD, enhance wound healing and associate with reduced 
inflammation 
We confirmed by GSEA that activated CD161+ Tregs were significantly enriched for 
wound healing genes, including soluble mediators, compared to other Treg populations 
(Supplementary Fig. 7a-b). Since CD161+ Tregs expressed CCR9 and ITGA4 (Fig. 3a and 
Supplementary Fig. 3a-b), we determined if they are enriched in the bowel during 
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inflammation by comparing Treg populations in matched peripheral blood to colonic biopsies 
of healthy individuals and those with Crohn’s disease (CD). There was mild enrichment of 
naïve and memory Tregs in colonic mucosa compared to blood. By contrast, there was a 
significant enrichment of CD161+ Tregs in healthy colons, which was even more pronounced 
in patients with IBD (Fig. 7a). LLT1, the ligand of CD161, is expressed in actively inflamed 
areas31, which we speculated would drive cytokine expression in CD161+ Tregs. We therefore 
tested the effect of CD161+ Treg supernatants on wound healing using a human epithelial 
colorectal adenocarcinoma cell line (Caco-2 cells) to approximate bowel epithelium. 
Supernatants from activated CD161+ Tregs increased and accelerated closure of the wound by 
almost two-fold compared to supernatant from memory Tregs or medium alone (Fig. 7b-c, 
Supplementary Fig. 7c and Supplementary Movies 1-3). Neutralization of IL-17 alone, 
IL17 together with IL-22, IL-4 or IL-10 impeded the wound healing capacity of supernatants 
of activated CD161+ Tregs, implicating these cytokines as mediators of wound healing (Fig. 
7d). Over-expression of BACH2 by lentiviral delivery in CD161+ Tregs significantly 
inhibited production of IL-17 and IL-4, with a similar but not significant trend in IL-22 and 
IL-10 (Fig. 7e and Supplementary Fig. 7d), supporting the notion that the wound healing 
program of CD161+ Tregs is dependent on reduced expression of the repressive BACH2 TF 
in these cells. 
The suppressive function of CD161+ Tregs and their ability to accelerate wound 
healing suggested that they may be beneficial in IBD. To explore this possibility, we 
examined RNA-seq from a large dataset of patients with CD (GSE57945) for expression of 
KLRB1, which encodes CD161. KLRB1 correlated negatively with 15 genes previously 
shown to be upregulated in inflamed compared to uninflamed CD mucosa50 (Fig. 7f). Of 
these, CXCL1, a clinical biomarker of CD, was significantly more highly expressed in 
inflamed versus uninflamed CD mucosa, while KLRB1 expression was significantly higher in 
uninflamed CD mucosa (Fig. 7g). KLRB1 is expressed on both Tregs, which are IL7Rlo, and 
Th17 cells, that are IL7Rhi. We used GSE57945 as a training dataset to test the performance 
of KLRB1, IL7R and KLRB1/IL7R ratio to distinguish inflamed from uninflamed CD. The 
receiver operating characteristic (ROC) curve for KLRB1/IL7R was highly significant 
(AUC=0.77; p-value<0.0001) and performed well in comparison with CXCL1, slightly better 
than KLRB1 and substantially better than IL7R alone (Fig. 7h) when predicting inflamed 
versus uninflamed mucosa. We used two additional transcriptome datasets from CD mucosa 
as validation datasets. In all cases the KLRB1/IL7R predictor was higher in uninflamed CD 
mucosa (Fig. 7i) and distinguished inflamed from uninflamed mucosa (AUC range 0.63 to 
0.79; Fig. 7j), suggesting that tissue infiltration with CD161+ Tregs is associated with lower 
inflammation in CD. These data indicate that CD161+ Tregs are enriched in colonic mucosa, 
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particularly in IBD, where they suppress inflammation and produce soluble factors that 
accelerate epithelial barrier healing, having overall a beneficial effect on outcomes. 
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Discussion 
Tregs are necessary for the prevention of autoimmunity and are currently under 
investigation as a cell therapy intended to prevent or ameliorate autoimmune diseases or 
transplant rejection2. Understanding biologically important and clinically relevant Treg 
populations is key to elucidating disease mechanisms and tailoring immunotherapy 
appropriately. The ability of Tregs to express TFs of other lineages, such as GATA3, IRF4, 
T-bet and STAT38-11 for appropriate licensing and biological function suggests functional 
heterogeneity or “division of labor” among Tregs. There is evidence that inappropriate high 
expression of alternate TFs, such as T-BET, can reprogram Tregs to carry out inflammatory 
functions7 and this may be true of other lineage-associated TFs.  
Here we have delineated the CD161+ Treg population in humans, showing that it is a 
distinct, bona fide retinoic-acid dependent Treg sub-population enriched in the lamina 
propria. We show that it is highly suppressive, can enhance wound healing through soluble 
mediators and, importantly, is associated with regions of gut that have lower inflammation in 
Crohn’s disease. Transcriptional control over the properties of these cells involves a TF 
network in which BACH2, RORgt, RUNX1, FOSL2 and BATF, all play a role. We show that 
CD161 is expressed on a discrete population of human Tregs that are phenotypically 
CD4+CD25hiCD127loFOXP3+CD45RA–CD45RO+CD161+ and distinct from Tconv 
expressing CD161. Their TCR repertoire is unique and, importantly, distinct from Tconv and 
Th17 cells. Thus, it is highly unlikely that they are contaminating Tconv and we conclude that 
they are a distinct sub-population of Tregs with stable regulatory function. 
Our data suggest that CD161+ Tregs are either induced to develop or to specialize in 
the periphery. This is consistent with almost complete absence of CD161+ Tregs in human 
cord blood24 and the relatively small numbers in peripheral circulation. In mice, RORgt+ 
Tregs in the colon can either be induced to develop from naïve CD4+ T cells by the local 
microbiota to suppress intestinal inflammation, although these cells do not produce IL-1751,52, 
or from thymic Treg émigrés following immunization with MOG and CFA26. We identified 
that human CD161+ Tregs have a retinoic acid gene signature and that retinoic acid directly 
regulates CD161 expression through ATRA-RARA complex binding to KLRB1, the gene 
encoding CD161. Since the bowel is a retinoic acid-rich site, a key area for Treg generation 
and since CD161+ Tregs expressed CCR9, a gut-homing chemokine receptor, we were not 
surprised to find enrichment of CD161+ Tregs in the lamina propria, particularly in patients 
with IBD. This is consistent with previous data identifying inflamed bowel as a site of 
enrichment for FOXP3+IL-17+ T cells53. Thus, CD161+ Tregs appear to be either induced or 
migrate to lamina propria, potentially a key site for their function.  
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There are elements in the chromatin landscape of all three Treg populations we 
studied that are broadly accessible in all subsets. These include Treg lineage-associated loci, 
such as FOXP3, CTLA4 and IL2RA, which are consistent with similar expression of these 
proteins in all the subsets. Indeed, the regulome of CD161+ Tregs differed from memory 
Tregs by only ~500 OCRs, which is congruous with the relatively small transcriptional 
differences between them. The transcription factor circuitry explaining these differences is 
dominated by BACH2, which is itself expressed at lower levels in CD161+ compared to 
memory Tregs. The importance of low BACH2 expression for the development and/or 
persistence of these Tregs was demonstrated by excess of the CD161+ Treg subset in a 
patient with genetic haploinsufficiency of this TF. As BACH2 restricts expression of effector 
programs in T cells5, it is unsurprising that some de-repression by BACH2 imparts functional 
properties to Tregs that resemble those of conventional T cells, notably production of 
cytokines, without loss of suppressive phenotype. This is supported by the significantly 
diminished cytokine production evident on BACH2 over-expression in these Tregs. Of note, 
CCR9 is a classic BACH2-repressed gene5 and one of the most differentially expressed genes 
in CD161+ Tregs. Likewise, RORC, FOSL2 and BATF programs play important roles in 
Th17 lineage specification in conventional T cells48 and their altered activity in CD161+ Tregs 
appears mechanistically responsible for regulating genes involved in wound healing. 
The role of CD161 itself in Tregs is noteworthy. Its cognate ligand, LLT1, is 
expressed on activated DCs and in actively inflamed areas31, so it is likely that that cross-
linking of CD161 will occur in inflamed areas of bowel. Indeed, single nucleotide 
polymorphisms in LLT1 are associated with IBD in humans32. We report that CD161 cross-
linking is co-stimulatory to CD161+ Treg activation and synergizes with CD3/CD28-mediated 
signals to induce cytokine secretion. This is in agreement with previous data suggesting that 
CD161 interaction with its cognate ligand stimulates proliferation and cytokine secretion on 
other T lymphocytes28 but contrasts with CD161 ligation on NK cells, which causes NK cell 
inhibition44,45. This suggests that any signal transduced by CD161 has effects that are cell-
type and possibly context-dependent.  
Although the correlation between CD161 expression and the Th17 program has been 
previously shown in Tconv30, it was unexpected to find the transcriptomes of activated 
CD161+ Tregs to encode a complex cytokine cocktail. Since IL-17 can have pro-
inflammatory functions associating it with multiple autoimmune diseases54 it is possible that 
their expression of IL-17 could denote a pro-inflammatory function. Indeed, some murine 
studies suggest that RORgt+ Tregs can convert to pathogenic cells that promote autoimmunity 
and cancer55,56. Our data, however, indicate that actively IL-17-producing Tregs continue to 
remain highly suppressive and we found no evidence that CD161+ Tregs are a transitional or 
unstable population. This is consistent with some studies in which adoptive transfer of IL-17 
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producing Foxp3+RORγt+ T cells in mice supports a stable and suppressive effect on gut 
inflammation57. The cytokine profile of CD161+ Tregs could denote alternative functions in 
addition to cellular suppression and one such function of Tregs is a potential role in wound 
healing58. In fact, several of the cytokines produced by CD161+ Tregs have established roles 
in wound healing, especially in the gut. Multiple studies have shown that IL-17 can promote 
repair of damaged intestinal epithelium and protect from excessive inflammation in colitis 
models59,60. Indeed, IL-17 blockade exacerbates colitis in both human and mouse models61,62. 
The same “protective” role has also been described for IL-22 by studies showing its role in 
inducing intestinal epithelial regeneration and protection from GvHD63 as well as dampening 
inflammation in models of IBD64 and ulcerative colitis65. In conclusion, these data would 
support the notion that enhancing CD161+ Tregs at the site of inflammation, for example, by 
cell therapy, may prove beneficial, in IBD.  
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Figure legends 
Figure 1. CD161+ Treg are a discrete population of memory Tregs. (a) viSNE plots of 
CD4+ T cells clustered using surface and intracellular markers. Shown are heatmaps for 
expression of indicated markers. White arrow highlights expression of CD161 within Tregs; 
(b) overlaid contour plots of T cell subsets, coloured by density, to highlight sub-populations 
of Tregs and Tconv; (c) 2D minimum spanning tree showing population nodes of CD4+ T 
cells. Node size represents cell number and color CD161 median intensity. Grouped together 
are naïve (circled in orange), memory (circled in yellow) and CD161+ (circled in purple) 
Tregs, as well as populations of naïve (circled in black), memory (circled in black) and 
CD161+ (circled in red) Tconv; (a-c) show representative data from n=3 experiments; (d) 
representative spectratype histograms from n=3 experiments showing percentage of unique 
CDR3 sequences (templates) versus CDR3 length for the three highest (BV05, BV06 and 
BV07) and one of the lowest (BV19) TCRBV families contributing to the overall TCR 
repertoire in the indicated populations; (e) average Morisita-Horn Similarity Index of total 
TCRVB repertoire between the T cell populations (cumulative data from n=3 experiments); 
and (f) dendrogram showing linkage distance based on the Morisita-Horn Similarity Index.  
Figure 2. CD161+ Tregs have classical features of bona fide Tregs. (a) number of 
differentially expressed genes between the sub-populations of freshly isolated Tregs; (b-c) 
Gene Set Enrichment Analysis (GSEA) plots for genes associated with other CD161+ cells (b) 
and core human Treg signature genes (c) comparing freshly isolated memory to CD161+ 
Tregs; (d) FOXP3 expression by sub-populations of Tregs and Tconv, showing representative 
flow cytometry plots (left) and cumulative data (mean + sem; right); (e) mean percentage 
CpG methylation of conserved CpGs (with chromosomal coordinates) at the FOXP3 TSDR, 
IL2RA and CTLA4 loci of naïve, memory, CD161+ Tregs and Tconv of 3 male donors. n=3 
independent experiments in a-e; ****p<0.0001.  
Figure 3. CD161 expression is regulated by retinoic acid. (a) GSEA for ATRA-regulated 
genes in human Tregs comparing freshly isolated memory to CD161+ Tregs. Classic ATRA-
regulated genes within the leading edge of core enriched genes (see Supplementary Fig. 4a) 
are annotated. In bold are gut homing receptors; (b) expression of CD161 and CCR9 on Tregs 
cultured with and without ATRA for 2 days; shown are representative flow cytometry plots 
(left) and cumulative data from n=3 experiments (right); p-values indicate comparisons with 
2µM ATRA; (c) representative assay of ALDH activity in DCs from n=3 independent 
experiments; (d) representative flow cytometry plots (left) and cumulative data (right) from 
n=3 independent experiments showing CD161 expression on Tregs before (fresh) and after 5 
days either with medium alone or co-culture with DCs in the presence or absence of the pan-
RAR inverse agonist, BMS493; (e) RARA ChIP-qPCR for binding sites in KLRB1 and 
CCR9, showing percentage of input; shown are representative examples from n=2 
independent experiments. Bar charts show mean + sem throughout; *p<0.05, **p<0.01, 
***p<0.001.  
Figure 4. CD161+ Tregs are regulatory both in vitro and in vivo. (a-b) In vitro Treg 
suppression assay showing representative CFSE dilution histograms of Tconv co-cultured 
with and without Tregs (a) and cumulative IC50 of memory and CD161+ Tregs from n=4 
experiments (b). Note that only one out of the 4 naïve Treg donors tested reached 50% 
suppression, therefore the mean IC50 was not calculated for the naïve Treg population. (c) 
Xeno-graft versus host disease with and without 2:1 PBMC : Treg injection, showing survival 
plots (left panel; * p<0.05 compared to PBMC alone) and clinical severity (right panel). 
Shown is one experiment from two independent experiments carried out with n=5 mice in 
each group. *p<0.05, **p<0.01, ****p<0.0001.  
Figure 5. CD161 ligation is co-stimulatory and induces cytokine production from 
CD161+ Tregs. (a) differentially expressed genes following 4h stimulation of CD161+ Tregs 
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with anti-CD3/CD28; (b) venn diagram of transcriptional differences between freshly isolated 
and in vitro anti-CD3/CD28-activated CD161+ and memory Tregs; (c) heatmaps of 
differentially expressed genes common to fresh and activated cells (lower panel) and specific 
to the activated condition (right panel), with cytokine genes highlighted in inset. Data in a-c 
are from 3 independent experiments; (d) concentration (pg/ml) of stated cytokines in 
supernatants of naïve, memory and CD161+ Tregs after 3 days of polyclonal activation with 
anti-CD3/CD28 (cumulative data from n=6 experiments); (e) suppression assay showing cell 
trace violet dilution in proliferating Tconv cultured alone or in co-culture with stated 
populations of Tregs (Treg: Tconv ratio of 1:2). Shown are representative plots (left) and 
cumulative data from n=3 independent experiments (right); (f) concentrations of stated 
cytokines in supernatants of FACS-sorted CD161+ Tregs stimulated for 3 days with either 
aCD3+aCD28+IgG2 or aCD3+aCD28+aCD161-coated magnetic beads (cumulative data 
from n=4 experiments). Bar charts shown mean + sem throughout. *p<0.05, **p<0.01, 
***p<0.001, ****p<0.0001.  
Figure 6. Genome-wide chromatin landscapes define the regulatory circuitry of CD161+ 
Tregs. (a-b) heatmap showing signal intensity of each ATAC peak and clustering of peaks 
into three groups (a) with representative examples of open chromatin regions (OCRs) from 
the three clusters (b - highlighted in blue are OCRs corresponding to ATAC peaks in the 
heatmap; (c) transcription factor (TF) footprints enriched relative to background in each 
cluster of ATAC peaks, with corresponding TF family indicated; (d) GSEA plots for 
BACH2-, RORgt-, BATF-, FOSL2- and RUNX1-regulated genes, comparing memory to 
CD161+ Tregs; (e) percentage of differentially expressed genes (DEG) between CD161+ and 
memory Tregs that can be explained by each TF, with Fisher Exact test p-values indicated; (f) 
CD161 expression on CD4+CD25hiCD127loCD45RA– Tregs of healthy ange and sec-matched 
donors (BACH2WT/WT) and a patient with BACH2 haploinsufficiency (BACH2WT/L24P); shown 
are representative flow cytometry plots (left) and data from two independent experiments 
(right); (g) Venn diagram showing shared and unique DEGs regulated by TFs (see also 
Supplementary Fig. 6e) (left) and corresponding function for those DEGs (right). Data for 
Fig. 6a-e and g are from n=3 independent experiments.  
Figure 7. CD161+ Tregs accelerate wound healing and are associated with lower 
inflammation in IBD. (a) enrichment of Treg sub-populations in colons relative to blood of 
healthy subjects and patients with Crohn’s disease (CD) (n=3 paired samples per group). Bar 
charts show mean + sem; (b-c) wound healing assay showing growth of Caco-2 cells cultured 
with medium alone or medium supplemented with culture supernatants (snt) of activated 
memory or CD161+ Tregs. Shown are representative still images captured over time (0, 72, 96 
and 120h) (b) and percentage of open wound over time from n=3 independent experiments; 
(d) Fraction of open wound at the end of culture of Caco-2 cells in the presence of culture 
supernatants from activated CD161+ Tregs in the presence of blocking antibodies to stated 
cytokines or isotype control. Shown are cumulative data from n=3 independent experiments. 
(e) concentration (pg/ml) of stated cytokines in supernatants of CD161+ Tregs transduced, or 
not, with control lentivirus or lentivirus encoding BACH2 (cumulative data from n=6 
experiments); (f) correlation matrix of indicated transcripts in bowel specimens of patients 
with active CD; (g) violin plots showing distribution of CXCL1 (left) and KLRB1 (right) 
expression in inflamed and uninflamed biopsies of CD; (h) ROC curves showing performance 
of CXCL1, IL7R, KLRB1 and KLRB1/IL7R ratio to discriminate inflamed (n=157) versus 
uninflamed CD or non-IBD tissue (n=56). AUC and p-values are indicated. (h-i) 
KLRB1/IL7R ratio in transcriptomes of inflamed and uninflamed sites of CD (h) and AUC + 
95% CI of KLRB1/IL7R ROC curves to distinguish the two (i). In i, area of circles indicates 
sample size. Source data for f-h: GSE57945; i-j: GSE20881 and Häsler et al., 2016. *p<0.05, 
**p<0.01, ***p<0.001, ****p<0.0001.  
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Supplemental Figure and Table legends 
Supplementary Fig. 1. CD161+ Tregs are a discrete population of memory Tregs. (a) 
heatmap showing signal intensity of selected markers for each node of the populations shown 
in Fig. 1c; (b-e) clustering of populations of Tconv and Tregs by single cell RNA-seq 
(scRNAseq) showing tSNE plot of 2636 cells from n=3 independent donors separated into six 
major (clusters 0-6) and two minor (clusters 7-8) clusters (b), feature plots showing 
expression of three Treg markers (IL2RA encoding CD25, IL7R encoding CD127 and 
FOXP3 encoding FOXP3), KLRB1 (encoding CD161) and two naïve/memory markers 
(SELL encoding CD62L and CCR7 encoding CCR7) (c), heatmap showing top 20 
discriminatory genes per cluster with representative genes of each cluster indicated (d) and 
population clustering (e) based on expression of the transcripts shown in c. Clusters in b are 
color-coded and labelled according to expression of the markers shown in e. (f) Clustering of 
Tconv and Treg sub-populations using protein expression data sourced from CyTOF in Fig 
1a incorporating the same markers as in (e) and also including CD45RA and CD45RO. 
Clustering of sub-populations in (f) is similar to that from scRNAseq (e). (g-h) viSNE plots 
(g) and 2D minimum spanning tree (h) of CD4+ T cells clustered following staining with anti-
CD4, anti-CD25, anti-CD127, anti-CD45RA and anti-CD161 for flow cytometry. Shown in g 
are heatmaps for expression of indicated markers, with arrow indicating CD161 expression in 
Tregs. Nodes size in h represents cell number and color CD161 median intensity. Grouped 
together are naïve (circled in orange), memory (circled in yellow) and CD161+ (circled in 
purple) Tregs, as well as populations of naïve (circled in black), memory (circled in black) 
and CD161+ (circled in red) Tconv. (g-h) show representative data from n=4 experiments. (i) 
representative example of FACS sorting strategy for naïve (orange), memory (yellow) and 
CD161+ Tregs (purple); (j) proportions of each Treg sub-population in healthy human donor 
peripheral blood (cumulative data from n=10 donors); (k) representative (upper panels) and 
cumulative (lower panels) expression of TCR Va24-Ja18 and Va7.2 in total CD4+ T cells 
and CD161+ Tregs. Both cell types show minimal expression of these invariant TCR chains. 
Data from n=3 independent experiments; bars show mean + sem. (l) Contribution of the three 
highest (BV05, BV06 and BV07) and one of the lowest (BV19) TCRBV families to the 
overall TCR repertoire in naïve, memory and CD161+ Tregs as well as CD161+ and CD161– 
Tconv cells; data from n=3 independent experiments; bars show mean + sem. (m) average 
percentage of TCR sequences either unique or shared among naïve, memory and CD161+ 
Tregs, CD161+ and CD161– Tconv cells (cumulative data from n=3 experiments). 
Supplementary Fig. 2. Transcriptome and methylome of CD161+ Tregs. (a) principal 
component analysis (PCA) 2D mapping of variance in expression of transcripts in freshly 
isolated Naïve, Memory and CD161+ Tregs (n=3); (b-d) scatter plots showing correlation 
between mean gene expression of freshly isolated Treg sub-populations; (e-f) GSEA plots for 
core human Treg signature genes comparing freshly isolated naïve to memory Tregs (e) and 
to CD161+ Tregs (f); (g) schematic representation of FOXP3, IL2RA and CTLA4 gene loci 
showing the target sequence and conserved CpGs assayed for methylation analysis in Fig. 2e; 
(h) mean region methylation percentage of FOXP3 TSDR, IL2RA and CTLA4 loci from 3 
male donors (data from n=3 independent experiments).  
Supplementary Fig. 3. Regulation of CD161 by retinoic acid. (a) heatmap of leading edge 
(core enriched) genes from GSEA for ATRA-regulated genes comparing freshly isolated 
memory to CD161+ Tregs (Fig. 3a). Data from n=3 independent experiments. (b) CCR9 
surface protein expression on memory and CD161+ Tregs; shown are representative flow 
cytometry plots (left) and cumulative data from n=3 independent experiments (right). (c) 
CD161 expression on Tregs co-cultured for 5 days with DCs with and without BMS493 at 
increasing concentrations. Shown are representative plots (left) and cumulative data from n=3 
independent experiments. (d-e) sequence logo for RARA DNA motif (d) and schematic 
representation of the KLRB1 and CCR9 gene loci (±5kb) showing the predicted binding sites 
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of RARA (e); red arrowhead indicates the binding site for CCR9 selected for analysis in 
ChIP-qPCR. Bars show mean + sem throughout the figure. *p<0.05, ** p<0.01. 
Supplementary Fig. 4. CD161+ Tregs are highly regulatory. (a-b) cumulative mean 
percentage suppressive function of freshly isolated naïve, memory and CD161+ Tregs from 
Fig. 4a (n=4 experiments) (a) and representative IC50 calculation (b; dashed arrows show the 
IC50 for CD161+ and Memory Tregs). (c) cumulative mean percentage suppressive function 
of memory and CD161+ Tregs after in vitro expansion for two weeks (n=4 experiments). (d) 
suppression of Tconv proliferation when in direct contact with Tregs or when separated by a 
transwell at a Treg:Tconv ratio of 1:1 (cumulative data from n=4 independent experiments); 
(e) suppressive function of Tregs under neutral (null) conditions or in the presence of 
blocking antibodies directed against CD161, PDL1, TGFbRII or IL10R, all at a Treg:Tconv 
ratio of 1:2 (cumulative data from n=3 independent experiments); (f) suppressive function of 
CD161+ Tregs under neutral (null) conditions or in the presence of Th1 and Th17 skewing 
conditions, all at a Treg:Tconv ratio of 1:2 (cumulative data from n=3 independent 
experiments); (g) expression of perforin, granzyme A and B in sub-populations of Tregs, with 
NK cells as positive control; shown are representative flow cytometry plots for each marker 
(left) and cumulative data from n=3 independent experiments (right). Bar charts show mean + 
sem throughout the figure. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. 
Supplementary Fig. 5. CD161+ Tregs produce cytokines on activation. (a) differentially 
expressed genes following 4h stimulation of memory and naïve Tregs with anti-CD3/CD28; 
(b) volcano plot showing significant genes differentially expressed in CD161+ Tregs after 4h 
activation with anti-CD3/CD28; differentially expressed genes are shown in blue; red 
indicates significantly upregulated cytokine genes that are differentially expressed compared 
to memory Tregs (see Fig. 5c); orange indicates other cytokine genes of interest upregulated 
in activated CD161+ Tregs. a-b are from 3 independent experiments; (c-d) cell sorting of IL-
17+ and IL-17– CD161+ Tregs by surface IL-17 capture. Shown are (c) representative flow 
cytometry plots showing double staining for intracellular and extracellular (captured on the 
surface) IL-17 with (right) and without (left) fixation and permeabilization and (d) sorting 
strategy using IL-17 surface capture and post-sort purity for the IL-17+ and IL-17– fractions of 
CD161+ Tregs.  
Supplementary Fig. 6. Global analysis of Treg regulomes. (a) open chromatin regions 
(OCRs) at prototypical Treg gene loci; (b) genomic distribution of ATAC peaks (promoter, 
intragenic or intergenic regions) in the three groups shown in Fig. 6a; (c) p-values for 
transcription factor (TF) motifs shown in each cluster in Fig. 6c; (d) expression of key TFs 
participating in gene regulation in CD161+ Tregs. Shown are normalized signal intensity 
(mean + sem) from n=3 microarrays for each Treg population; (e) integrated TF network 
showing contribution of each TF to DEGs and overlap between them (fold difference in 
expression of each TF is also indicated next to the TF).  
 
Supplementary Fig. 7. CD161+ Tregs accelerate wound healing. (a-b) GSEA plots for 
wound healing associated genes (a) and wound healing associated soluble mediators (b) 
comparing activated CD161+ to memory Tregs. Data from n=3 independent experiments; (c) 
wound closure rate of Caco-2 cells cultured in the presence of either medium alone or 
medium supplemented with culture supernatants (snt) from activated memory or CD161+ 
Tregs. Shown are cumulative data from n=3 independent experiments. Bar chart shows mean 
+ sem; *p<0.05. 
Supplementary Table 1. List of differentially expressed genes (DEGs). Listed are DEGs in 
comparisons of freshly isolated Tregs to each other (tab 1) and transcriptional changes in each 
population when comparing CD3/CD28-activated cells to freshly isolated cells (tab 2).  
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Supplementary Table 2. Expression of killer cell lectin like receptors (Klr) in wild-type 
mouse Tregs. Shown are RPKM values (n=6) for Klr gene transcripts, Foxp3 and Actin. Data 
from Feng et al., 2014, GSE58905. 
Supplementary Table 3. Open chromatin regions (OCRs) from ATAC-seq. Listed are 
genes with OCRs conforming to cluster 1 (naïve Tregs-specific), cluster 2 (shared between 
CD161+ and memory Tregs) and cluster 3 (CD161+ Tregs-specific). 
 
Supplementary Table 4. List of conjugated antibodies used for mass cytometry. 
Supplementary Table 5. Gene lists used for gene set enrichment analyses. 
Supplementary Movies 1-3. Wound healing assay. Movies show growth of Caco-2 
cells cultured with medium alone (Supplementary Movie 1) or medium supplemented 
with culture supernatants (snt) of activated memory (Supplementary Movie 2) or 
CD161+ Tregs (Supplementary Movie 3). Time-lapse images were recorded from 0-
120h. 	 	
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Online methods 
T-cell separation, sorting, and flow cytometry  
Human PBMCs (peripheral blood mononuclear cells) and T cells subsets were purified from 
either leukodepletion cones (Blood Transfusion Service, London) or fresh blood of healthy 
volunteers. Tregs were isolated by initially enriching with CD4+ T Cell Isolation Kit II 
(Miltenyi Biotec), cells were subsequently stained with mouse anti human CD4 (OKT4), 
CD127 (eBioRDR5), CD45RA (HI100, all from eBiosciences) and CD25 in PE (both 2A3 
and M-A251) and CD161 (DX12, all from BD Biosciences); PE-labelled cells were then 
captured using anti-PE MicroBeads (Miltenyi Biotec) to enrich for Tregs, pre-sorting. Cells 
were FACS sorted for surface markers to separate naïve 
(CD4+CD25hiCD127loCD45RA+CD161-), memory (CD4+CD25hiCD127loCD45RA-CD161-), 
and CD161+ (CD4+CD25hiCD127loCD45RA-CD161+) Tregs. Sorting of naïve Tconv 
(CD4+CD25-CD45RA+CD161-), total Tconv (CD4+CD25-) and Th17 (CD4+CD25-CD45RA-
CD161+) cells was performed using the same panel. Intracellular staining for FOXP3 
(PCH101, eBioscience) was carried out using the Foxp3 / Transcription Factor Staining 
Buffer Set Kit (eBioscience) according to manufacturer’s instructions. For intracellular 
staining of cytokines and transcription factors cells were activated for 4 hours with PMA (50 
ng/mL) and ionomycin (1 mM, both from Sigma) with the addition of Brefeldin A (3 μg/mL; 
eBioscience) before staining. Additional staining of Tregs were further stained for invariant 
chains TCRVa24-Ja18 (6B11) and TCR Va7.2 (3C10, both from Biolegend), perforin (dG9, 
eBioscience), granzyme A (GB11, Biolegend) and granzyme B (CB9, Biolegend) using 
appropriate flurochrome-conjugated antibodies. Flow cytometry data were acquired on an 
LSR Fortessa (BD) and subsequenrly analyzed using FlowJo version 10.1 (TreeStar Inc.). 
Mass Cytometry (CyTOF) 
2x106 CD4+CD127lo cells were isolated using RosetteSep™ Human CD4+CD127low T Cell 
Enrichment Cocktail (STEMCELL Technologies) before extracellular and intracellular 
staining with metal conjugated antibodies. For full list of both antibody panels refer to 
Supplementary Table 4. CyTOF-2 mass cytometer (Fluidigm) was used for data acquisition 
and beads (Ce140) were used for normalization 1. 320,000 cells were proportionally sampled 
from all individuals to perform automated clustering. Data were initially processed and 
analysed using Cytobank 1; CD4 sample “cleanup” was performed by gating on intact (191Ir+ 
DNA stain), no beads (Ce140-), live (103Rh-), no B cells CD19-CD20- (Nd142), no 
neutrophils CD15- CD123- (Eu151), CD34- (Er166), CD45+(Y89), CD3+ (Sm154) and CD4+ 
(Nd145) T cells. Mass-cytometry complex data was analysed using viSNE, in combination 
with SPADE, to identify distinct subpopulations 2,3 using the following parameters: CCR6 
(141Pr), CD45RA (143Nd), CCR4 (149Sm), CD161 (150Nd), CD103 (152Sm), CD62L 
(153Eu) Helios (156Gd), CCR7 (159Tb), Tbet (160Gd), CD95 (161Dy), CXCR3 (163Dy), 
CD45RO (164Dy), GATA3 (167Er), CCR9 (168Er), CD25 (169Tm), Foxp3 (171Yb), 
CXCR4 (173Yb), HLA-DR (174Yb), CD127 (176Yb). viSNE and SPADE plots were 
generated using Cytobank Inc. (CA, USA). When indicated in the figure legend, figures were 
overlaid for demonstration purpose. 
T cell culture 
Unless indicated otherwise, cells were cultured in X-Vivo 15 with Gentamycin and PR 
(Lonza) supplemented with Penicillin-Streptomycin Glutamine (PSG, Thermo Fisher) and 5% 
human AB serum (Biosera), henceforth shortened to X-Vivo 5% HS; cells were then seeded 
at 106cell/ml. 
 
For the evaluation of the effect of ATRA on CD161 expression, 250,000 total Tregs were 
isolated and stimulated for 48h with 1:1 ratio of αCD3/CD28 Dynabeads in X-Vivo 5% HS 
supplemented with 100IU/ml of IL-2 (Proleukin, Novartis), in the presence of 0, 0.02, 0.2 or 
2μM ATRA (Sigma-Aldrich); cells were then stained for CD4, CD161 and CCR9 and the 
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effects of ATRA on expression of CD161 (stained with anrtibody clone DX12 from BD) and 
CCR9 (stained with antibody clone L053E8 from Biolegend) was evaluated by flow 
cytometry. 
 
For Treg expansion to facilitate in vivo models sorted memory and CD161+ Tregs were 
cultured in X-Vivo 5% HS supplemented with 1,000 IU/ml IL-2 and stimulated with 
αCD3/CD28 Dynabeads at a 1:1 ratio for 2-3 rounds of expansion of 10-14 days each. Beads 
were removed by magnetic adherence following each round of stimulation and fresh 
αCD3/CD28 Dynabeads (1:1 ratio) added. After the last round of expansion, beads were 
removed and the cells were rested for 2 days before injection. Cell viability was close to 
100% prior to each in vivo experiment. 
 
To evaluate the effects of CD161 crosslinking on cytokine production, CD161+ Tregs were 
cultured for 3 days in X-Vivo 5% HS, supplemented with 100 IU/ml IL-2 and stimulated 1:1 
with microbeads from the T cell activation/expansion kit (Miltenyi Biotec) loaded with anti-
CD3 and anti-CD28 following manufacturer’s instructions with the addition of anti-CD161 
(191B8, MiItenyi) or IgG2a (eBM2a eBioscience). 
Treg suppression assay 
Cryopreserved Tconv cells (CD4+CD25-) were used as target cells throughout. These were 
isolated by negative selection of CD4+ T cells followed by positive selection of CD25+ T cells 
using miniMACS CD4+CD25+ T Regulatory Cell Isolation Kit (Miltenyi Biotec, UK) 
according to manufacturers’ instructions. Tconv cells were obtained from the CD25- negative 
fraction. Cryopreserved Tconv were thawed and labelled with either 2.5μM 
Carboxyfluorescein diacetate, sucinnimydil ester (CFSE) (Molecular Probes, USA) or 1μM 
CellTrace Violet (CTV) (Molecular Probes, USA) according to manufacturers’ instructions. 
Tconv cell viability was routinely greater than 95% prior to suppression assay. Suppression 
assays were conducted in X-Vivo 5% HS and U-bottom 96-well plates incubated at 37°C, 5% 
CO2 for 5 days, at constant Tconv cell number (105 cells) and Treg:Tconv ratio of 1:1 or 1:2, 
as indicated. Where indicated, Treg numbers were titrated to result in a Treg:Tconv ratio of 
1:1 to 1:32 ratio. Cells were stimulated with αCD3/CD28 Dynabeads (bead:cell ratio of 1:40) 
and CFSE/CTV dilution was assessed by flow cytometry on day 5. Percentage of suppression 
and IC50 were calculated as previously described 4. Where indicated, Treg suppression was 
also evaluated in the presence of either 10μg/ml αCD161 (BD Pharmingen), 10μg/ml αPDL-1 
(eBioscience), 10μg/ml αIL-10R (Sigma), 1μg/ml αTGFBRII (R&D) or in the presence of 
Th1 (40ng/mL IL-12 (Biolegend) and 5µg/mL aIL-4 (R&D)) or Th17 (40ng/mL IL-1b 
(R&D) and IL-6, 10ng/mL TGF-b1 (both from Biolegend), 50ng/mL IL-23 and 5µg/mL aIL-
4 and aIFNg, all from R&D) skewing conditions. 
 
For transwell suppression assay the HTS Transwell-96 Permeable Support with a 0.4μm Pore 
Polycarbonate Membrane system (Corning) was used. Suppression was tested at a 1:1 
Treg:Tconv ratio and Tconv were seeded in the lower compartment of the transwell plate, 
while Tregs were seeded on to the upper compartment. Cells in both the upper and lower 
chambers were stimulated with αCD3/CD28 Dynabeads (bead:cell ratio of 1:40).  As 
reference of standard suppression, Tregs and Tconv were also co-seeded in the lower 
compartment. 
Gene expression analysis 
200,000 naïve, memory and CD161+ Tregs were either sorted from fresh blood directly into 
Trizol LS (Ambion) for baseline genetic profile or cells were polyclonally activated post-
sorting for 4h with Dynabeads Human T-Activator CD3/CD28 (ratio 1:1) and then lyzed in 
Trizol LS. . RNA was isolated using RNeasy mini kit (QIAGEN) and Ovation PicoSL WTA 
System V2 (NuGEN Technologies) was used for reverse transcription and cDNA 
amplification steps. Fragmentation and labelling was performed using the Encore Biotin 
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Module (NuGEN Technologies); all kits were employed following manufacturer’s 
instructions. Samples were run on GeneChip® Human Gene 1.0 ST Array (Affymetrix Ltd). 
Data analysis was performed using Partek Genomic SuiteTM (Partek Incorporated). 
Thresholds for significance were set at 1.5-fold difference at p<0.05 for freshly isolated cells 
and 2-fold difference at p<0.05 for in vitro activated cells. 
 
Gene set enrichment analysis (GSEA) was performed using GSEA version 2.2.2 5. Datasets 
used for GSEA are shown in Supplementary table 1. Core human Treg genes were sourced 
from 6; genes associated with CD161+ cells were obtained from 7. The ATRA-regulated gene 
list was generated by microarray from human Tregs treated, or not, with ATRA (Scottà et al. 
unpublished data). Genes regulated by RORC, BATF, and FOSL2 were curated from 
comparison of wild type and single gene knock-out Th17 cells from 8(GSE40918), RUNX1 
from wild type and Cbfbeta knockout Tregs 9 (GPL1261) and BACH2 from wild type and 
Bach2 knockout Tregs 10(GSE45975), all at a significance threshold of 1.5-fold change and 
p<0.05. Mouse gene symbols were converted to human homologs using the BioMart data-
mining tool in ensemble: http://www.ensembl.org/biomart/martview. General wound healing 
associated genes were curated from published gene lists 11-13, the “resolve wound healing and 
fibrosis-related genes” dataset (http://www.resolve-whfg.appspot.com/list/Human/) and 
“wound healing RT2 profiler PCR array” (Qiagen). Wound healing associated soluble 
mediators were defined as the online dataset for “cytokines in wound healing (R&D 
Systems)” supplemented with cytokines and other soluble mediators from the general wound 
healing associated genes list. 
 
Single cell RNA-sequencing 
The single cell sequencing experiment was performed using the 10X Genomics’ Chromium 
Single Cell 3’ gene expression V2 kit following the manufacturer’s instruction. CD4+CD25+ 
T cells were freshly isolated from peripheral blood of 3 healthy donors. Cells were captured 
for each sample and libraries were sequenced on the Illumina Hiseq 3000 instrument. Raw 
reads from the 3 samples were combined and processed using 10x Genomics Cell Ranger 
v2.1 14. The result was summarized into an expression matrix with the unique molecular 
identifier (UMI) count for every cell and every gene. Genes expressed in < 3 genes and cells 
with < 200 genes detected or > 5% of the total UMI count in mitochondrial genes were 
removed, resulting a final matrix comprising 2,636 cells and 15,357 genes. Dropouts were 
imputed using DrImpute 15. We analyzed data using the R package Seurat 16 with default 
parameters if not specified. Top 15 principal components were used to compute the tSNE 
plot. Resolution was set to 0.4 for clustering. 
Methylation analysis 
For CpG methylation analysis 250,000 cells from each desired population were FACS sorted. 
CpG methylation analysis was determined by pyrosequencing of bisulphite-modified genomic 
DNA. Methylation analysis was conducted by EpigenDx, as previously described by 17. CpG 
methylation of FOXP3 TSDR (ADS783FS2), IL2RA (ADS4564FS) and CTLA4 
(ADS3074FS2) loci shown in Supplementary Fig. 2g were evaluated. 
TCRBV sequencing 
For TCRBV sequencing 250,000 cells from each population were FACS sorted. 
Amplification and sequencing of TCRB CDR3 was performed by Adaptive Biotechnologies 
using the immunoSEQ Platform 18,19. Analysis was performed using ImmunoSEQ analyser for 
spectratyping analysis and clone sharing among samples; to assess the overlap in TCR 
composition between populations, the Morisita–Horn similarity index 20 was calculated using 
R-Studio. Only productive (in frame and without included STOP codon) amino acidic (VJ) 
sequences were analysed; the number of both common and specific sequences for each 
combination of populations was used to calculate the percentage of unique and shared 
sequences within the different populations.  
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DCs generation, MLR and CD161 induction 
From PBMCs, CD14+ cells were isolated with CD14 microbeads (Miltenyi Biotec) and DCs 
generated by culturing for 5 days in X-Vivo 5% HS supplemented with 50ng/ml GM-CSF 
(Peprotech) and 800U/ml IL-4 (R&D). Maturation of the DCs was achieved by culturing for 
further 48h with 50ng/ml GM-CSF, 800U/ml IL-4, 10ng/ml of IL-1b, IL-6 (eBioscience), 
TNF-a (Biolegend) and 1µg/ml of PGE2 (BioVision) and LPS (Sigma-Aldrich). To assess 
the capacity of the DCs to produce ATRA the ALDEFLUOR kit (STEMCELL Technologies) 
was used to stain the cells for ALDH. Mixed lymphocyte reaction (MLR) was performed by 
co-culturing DCs with total Tregs for 5 days in the presence or absence of 1µM pan RAR 
inverse agonist (BMS493, Tocris Bioscience). 
RARA ChIP-qPCR 
JASPAR 21 was used to scan the sequences of both KLRB1 and CCR9 gene loci (± 5kb from 
gene body) for predicted binding sites of ATRA. 15x106 cells were cultured for 4h in X-Vivo, 
not supplemented with human serum, in the presence or absence of 2µM of ATRA (Sigma-
Aldrich). RARA ChIP-qPCR was then performed. Briefly, cells were fixed with 16% 
Formaldehyde (ThermoFisher) and harvested in PBS containing protease inhibitors Aprotinin 
(MP biochemicals), Leupeptin (Bachem), both at 1μg/mL and 1mM Phenylmethylsulfonyl 
fluoride (PMSF, Sigma). Frozen cell pellets were lyzed in SDS lysis buffer containing 
protease inhibitors and DNA sheared into lengths of 0.2-1Kbp using a Branson sonicator 
(11% power amplitude). Samples were resuspended in 2ml of ChIP dilution buffer (0.01% 
SDS, 1.1% Triton X-100 (Sigma), 1.2mM EDTA, 16.7mM Tris HCl pH8.1, 167mM NaCl in 
dH2O) containing protease inhibitors; 100µl of samples were taken as input DNA and stored 
for downstream qPCR. To reduce non-specific binding, samples were pre-cleared by 
incubation with salmon sperm DNA/protein A agarose-50% slurry (EMD Millipore). 
Chromatin immunoprecipitations (ChIPs) were carried out using 10μl/IP of RARA polyclonal 
antibody (Diagenode C15310155) and salmon sperm DNA/protein A agarose- 50% slurry. 
Slurry was then serially washed with Low salt wash buffer (0.1% SDS, 1% Triton X-100, 
2mM EDTA, 20mM Tris HCl pH 8.1, 150mM NaCl in dH2O) followed by High salt wash 
buffer (0.1% SDS, 1% Triton X-100, 2mM EDTA, 20mM Tris HCl pH 8.1, 500mM NaCl in 
dH2O), LiCl wash buffer (0.25M LiCl (Sigma), 1% NP40 (ThermoFisher), 1% deoxycholate 
(ThermoFisher), 1mM EDTA, 10mM Tris HCl pH 8.1 in dH2O) and finally twice with TE 
buffer pH 8 before elution form the beads with elution buffer (1% SDS, 0.1M NaHCO3). 
Cross-linking was reversed with 5M NaCl/ml and heating to 65°C for 4 hours; dissociated 
TFs and antibodies were digested by adding 0.5M EDTA, 1M Tris HCl (pH 6.5) and 
20mg/ml Proteinase K (ThermoFisher) followed by overnight incubation at 55°C. DNA was 
precipitated with isopropanol and re-dissolved in dH2O before purification with MinElute 
PCR Purification Kit (QIAGEN). Primers for KLRB1 (forward: 
GTCCCCACCCACATACACTT; reverse: AGAACAAATGAGCCTCCCAGA) and CCR9 
(forward: AGTTTCCCCTTATCCCAGCA; reverse: CAGCTACCCGATAACAACACG) 
were designed and used for quantification by qPCR. Percentage of input, normalising the 
signal obtained from the ChIP against the input sample, was calculated.  
Cytokine secretion measurement 
To evaluate the cytokine production of the different populations of Tregs after activation, 106 
naïve, memory and CD161+ Tregs were FACS sorted and activated for 3 days with 1:1 ratio 
of aCD3aCD28 Dynabeads and 100U/ml of IL-2. Cytokine protein levels were measured in 
the supernatant by either Th1/Th2/Th17 Cytometric Bead Array (CBA, BD) or LEGENDplex 
Human T helper Cytokine panel (Biolegend). To evaluate the effect of CD161 crosslinking on 
cytokine production 100,000 cells were stimulated for 3 days with ratio 1:1 microbeads 
coated with either aCD3aCD28IgG2 or aCD3aCD28aCD161 (T Cell Activation/Expansion 
Kit, Miltenyi Biotec, as previously described 7) and protein levels measured in the supernatant 
by LEGENDplex Human T helper Cytokine panel (Biolegend). 
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IL-17 capture assay 
106 CD161+ Tregs were FACS sorted and then stimulated with PMA and Ionomycin for 5h. 
IL-17 producing CD161+ Tregs were then labelled using the IL-17 Secretion Assay Kit 
(Miltenyi Biotec) according to manufacturer’s instructions and then FACS sorted into IL-17 
producing and non-producing cells. Cells were rested overnight and a standard suppression 
assay, including naïve and memory Tregs as controls, performed.  
Simultaneous staining of surface and intracellular IL-17 was carried out on 106 CD4+ T cells 
by incubating cells for an extra 2 hours in PMA/Io with supplementation of BD GolgiPlug, 
before washing and staining with surface IL-17 detection antibody (IL-17 Secretion Assay 
Kit, Miltenyi Biotec). Following extracellular staining and fixation/permeabilisation, 
intracellular staining was then performed with a second aIL-17 antibody conjugated with a 
different fluorochrome. To validate the specificity of the double staining, staining with the 
antibody for intracellular IL-17 was also performed on cells without 
fixation/pearmeabilization step, but after surface staining with IL-17 Detection antibody; lack 
of double positive cells in the control sample demonstrated that the staining for intracellular 
IL- 17 was specific. 
In vitro wound healing assay 
250,000 Caco-2 cells were seeded into CytoSelect 24-Well Wound Healing Assay plates 
(Cell Biolabs) in DMEM supplemented with 10% FBS (both from GIBCO) and 1% MEM 
Non-essential Amino Acid (NEAA, Sigma-Aldrich) and grown until confluence for 7 days. 
Sorted memory and CD161+ Tregs were stimulated for 3 days with 1:1 ratio of aCD3aCD28 
Dynabeads and 100U/ml of IL-2 in complete RPMI (GIBCO) with 10% v/v HS and 
supernatant collected. Supernatant from the cells was then diluted 1:4 with fresh DMEM 10% 
FBS 1% NEAA and added to the Caco-2 cells, after insert removal. As negative control 
RPMI 10% HS diluted with 1:4 with DMEM 10% FBS 1% NEAA was used. Time-lapse 
image capture was recorded using Biostation CT (Nikon) over a period of 120h. Percentage 
of open wound was calculated using the “wound-healing” tool on NIS Elements Advanced 
Research Microscope Imaging Software (Nikon). For evaluation of the effect of cytokine 
blocking on wound healing either IgG1a (5µg/ml) together with IgG2b Isotype (5µg/ml), 
aIL-17 (5µg/ml), aIL-22 (5µg/ml), aIL-4 (5µg/ml), aIL-10R (10µg/ml), aIFNg (5µg/ml), 
aIL-17 (5µg/ml) together with aIL-22 (5µg/ml) or aIL-10R (10µg/ml) together with aIL-4 
(5µg/ml; all antibodies from R&D sytems) were added to the wound healing assay; image 
capture was recorded at start and at 120h post culture. 
 
Patient biopsies 
Six consecutive patients who attended the endoscopy department at King’s College Hospital 
(London, UK) for a colonoscopy required in the context of their routine clinical care were 
consented for the study (REC 15/LO/1998). Three patients were recruited with an established 
diagnosis of Crohn’s disease (CD), based on conventional clinical criteria, and three without 
any history of chronic inflammatory bowel disease (IBD), but with gastrointestinal symptoms 
or anaemia that required investigation; these latter patients were then considered as “healthy 
individuals” with no diagnosis of CD. Peripheral blood was collected in EDTA tubes on the 
day of attendance to endoscopy and prior to colonoscopy. During colonoscopy 2mm biopsies 
were collected from inflamed sites in patients with CD or randomly for those without a 
diagnosis of IBD. Endoscopic findings of inflammation and/ or normal macroscopic 
appearances were confirmed by histopathology. 
 
PBMC were isolated following standard isolation protocol and colonic Lamina Propria 
Mononuclear cells (cLPMC) were isolated after digestion of the colonic tissue as previously 
described 22. Both PBMC and cLPMC were then stained for CD45, CD3, CD8, CD4, CD25, 
CD127, CD45RA and CD161. Total CD4+ T cells were initially defined as CD45+CD3+CD8-
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CD4+ and Tregs subpopulations were then selected following standard gating strategy, as 
previously described.  Treg populations were then compared in matched peripheral blood to 
colonic biopsy samples of healthy individuals and those with IBD. 
Severe xeno-graft-versus-host-disease (GvHD) model 
NOD/scid/IL-2Rg−/− (NOD.cg-PrkdcscidIl2rgtm1Wjl/SzJ) mice (NSG; The Jackson Laboratory) 
were used between 8-10 weeks of age. Animals were bred and maintained in the Biological 
Services Unit of King’s College London. All mice were kept under specific-pathogen-free 
conditions, and procedures were conducted in accordance with institutional guidelines 
(PPL70/7302) and the Home Office Animals Scientific Procedures Act (1986). Sorted 
Memory and CD161+ Tregs were cultured in X-Vivo 15 with Gentamycin and PR (Lonza) 
supplemented with 5% human AB serum (HS, Biosera), 1,000 IU/ml of IL-2 (Proleukin, 
Novartis) and stimulated with Dynabeads Human T-Activator CD3/CD28 (GIBCO) at a 1:1 
ratio for 2-3 rounds of expansion (10–14 days each). After the last round of expansion, beads 
were removed and the cells were rested for 2 days before injection into the mice. Human 
PBMCs (10x106) depleted of CD25+ cells were injected intravenously to induce xeno-GvHD 
with or without in vitro–expanded Memory or CD161+ Tregs (5×106) at a 2:1 PBMC:Treg 
ratio. Mice injected with PBS alone were used as negative control. Mice were monitored for 
symptoms of xeno-GvHD over time and experiment was carried on until either a clinical 
score greater than 6 or a weight loss greater than 15% from the initial weight was reached. 
Clinical GvHD score was calculated by applying a modified scoring system (adapted from 23: 
individual mice received a score of 0 to 2 for each criteria. 
 
Criteria Grade 0 Grade 1 Grade 2 
Weight loss <5% >5% to <10% >10% 
Posture Normal Hunching only at rest 
Severe hunching 
impairs movement 
Activity Normal Mild to moderately decreased 
Stationary unless 
stimulated 
Fur texture Normal Mild to moderate ruffling 
Severe 
ruffling/poor 
grooming 
Skin integrity Normal Scaling of paws/tail 
Obvious areas of 
denuded skin 
Lentiviral preparation 
Lentiviruses were prepared by transfecting HEK293T cells. 106 cells were plated in DMEM 
10% FCS and 1% PSG and transfected with 15µg of psPAX2 (Addgene), 5 µg of pMD2.G 
(Addgene) and 20µg of either Control or Bach2-expressing pLVX-EF1a-IRES-ZzGreen 
plasmids (Clonetech). The transfection mix was then added to an equal volume of CaCl2 
0.5M. The resulting solution was added dropwise to an equal volume of 2x HEPES buffered 
saline (HBS; Fluka, Sigma-Aldrich Company Ltd., Dorset, England) to precipitate the DNA. 
After an incubation of 30 minutes at room temperature, the prepared solution was added 
evenly, drop wise, to the cells and the plate was incubated at 37°C overnight. Two collections 
of supernatant containing viral particles were performed at day 3 and 4 post transfection and 
concentration was performed by addition of PEG-it Virus concentration solution (SBI, 
System Bioscience, Mountain View, U.S.A) following manufacturer’s instructions. After 
allowing 48 hours for virus precipitation, the solution containing the viral particles was spun 
at 1500g for 30mins at 4°C to obtain a viral pellet that was resuspended in 300µl of cold 
medium and stored at -80°C until used. 
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CD161+ Treg transduction 
Sorted CD161+ Tregs were stimulated for 3 days with aCD3/CD28 dynabeads (1:1 cell to 
bead ratio) in RPMI 10% HS supplemented with 100U/ml of IL-2. Cells were then counted, 
washed and resuspended at 106/ml. 100,000 cells were seeded in a 96 well plate and left 
overnight at 37oC; the following day 1X Transdux and Max Enhancer (TransDux Max kit, 
SBI) were added to each well in the presence or absence of 10µl of Control or Bach2 
lentiviruses. 3 days post addition of the virus aCD3/CD28 dynabeads were magnetically 
removed, cells fed with fresh medium and left at 37oC for a further 3 days. At the end of the 
transduction protocol, cells were counted, washed and resuspended at 106/ml and stimulated 
for another 3 days with aCD3/CD28 dynabeads (1:1 cell to bead ratio) in RPMI 10% HS 
supplemented with 100U/ml of IL-2. Supernatant was then collected and cytokine production 
was measured. 
CD161+ Treg transfection 
Sorted CD161+ Tregs were stimulated for 3 days with aCD3/CD28 dynabeads (1:1 cell to 
bead ratio) in RPMI 10% HS supplemented with 100U/ml of IL-2. Cells were then counted, 
washed and resuspended at 2x106/ml. 100,000 cells were then seeded in a 96 well plate and 
transfected with either All star Negative Control siRNA or HS_RORC_7 Flexitube siRNA 
(both from Qiagen) following manufacturer’s instruction; untransfected cells were used as 
baseline control. Cells were then cultured for 3 days at 37oC; supernatant was then collected 
and cytokine production measured. 
ATAC-Seq 
ATAC-seq was performed according to published protocol 24 with minor modification as 
described in 25. Paired-end libraries (50 cycles) were prepared according to ATAC-seq 
protocol (see above) with three biological replicates (i.e. cells from 3 different individuals) 
for each library. The sequencing was performed using Illumina 2000. To obtain the open 
chromatin regions, reads were aligned to hg19 using Bowtie v2.2.9 26 with parameters [--
maxins 175 --no-discordant --no-mixed]. Properly paired and uniquely mapped alignments 
were extracted. The open chromatin regions were identified using Homer findPeaks tool 27 
with parameters [-region -size 500 -minDist 50 -tbp 0].  All the open chromatin peaks were 
merged using bedtools 28 to obtain a set of all potential peaks. For each replicate, the 
differential set of open chromatin regions for each pair of samples (i.e. memory vs naïve, 
memory vs CD161, naïve v CD161) were extracted using homer getDifferentialPeaks with 
parameter –F 2 and the set of all potential peaks. For each pair of samples, the common peaks 
among three replicates were extracted using bedtools multiinter. All the common differential 
open chromatin regions were merged using bedtools and displayed using seqMINER 29 with 
three clusters. To identify motifs that are enriched in each cluster, we used homer 
findMotifsGenome on all known motifs with parameter [-size given]. 
 
Data analysis and statistical tools 
Statistical analysis was carried out using GraphPad Prism 7 (GraphPad software Inc., USA). 
All measures of variance were expressed as mean ± standard error of the mean (SEM) and for 
data comparison t-test, one- or two-way RM ANOVA were used as indicated. Data were 
considered statistically significant with p<0.05, p<0.01, p<0.001 or p<0.0001 and represented 
in figures as indicated. ROC curves were constructed in GraphPad Prism v7 (GraphPad 
software Inc) using the dataset from Haberman et al., 2014 (GSE57945) as a training set, 
taking inflamed versus uninflamed Crohn’s disease and healthy donor tissues as defined by 
the investigators. Test datasets were sourced from Noble et al., 2010 (GSE20881) and Häsler 
et al., 2016 30, classifying samples as either normal versus any inflammation (Noble et al., 
2010) or non-inflamed versus inflamed as defined by the investigators (Häsler et al., 2016).  
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